Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3903003
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
GSK3903003 is an investigational therapeutic vaccine developed by GSK for the treatment of chronic hepatitis B (CHB). It is a protein subunit vaccine composed of recombinant hepatitis B surface antigen (HBsAg) and recombinant hepatitis B core antigen (HBcAg), formulated with GSK's proprietary AS01B adjuvant system. Unlike prophylactic vaccines designed to prevent infection, GSK3903003 is intended to stimulate a robust, multi-specific T-cell response in individuals already chronically infected with the hepatitis B virus (HBV). The goal of this therapeutic intervention is to overcome the immune exhaustion characteristic of CHB and achieve a 'functional cure,' defined by the sustained loss of HBsAg. GSK3903003 is frequently evaluated in sequential or combination regimens with other antiviral agents, such as the antisense oligonucleotide bepirovirsen, to maximize the potential for viral clearance.
- Other names
- adjuvanted protein therapeutic hepatitis B vaccineGSK chronic HBV therapeutic vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)TLR4 (Toll-like receptor 4)HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on GSK3903003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3903003.